Loading…
STOP Neglected Diseases of Poverty Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Study, Treat, Observe, and Prevent Neglected Diseases of Poverty Act or the STOP Neglected Diseases of Poverty Act This bill directs the Department of Health and Human Services (HHS) to address neglected diseases of poverty in the United States. Among other activities, HHS must establish an interagency task force to provide recommendations to address neglected diseases of poverty in the United States; provide grants to states to implement surveillance systems to determine the prevalence, incidence, and distribution of such diseases; and increase awareness of neglected diseases of poverty among health care providers and the public.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2020 · fourth_quarter · Health Issues
Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; H.R.826, End Neglected Tropical Diseases Act; S.2675, Study, Treat, Observe, and Prevent Neglected Diseases of Poverty Act; Implementation of H.R.6201, Families First Coronavirus Response Act (P.L.116-127); Implementation of H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; Implementation of H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139); H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act; H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Energy/Nuclear
Issues related to - S. 2675 Energy Innovation Act - Energy Storage & Hydrogen; Energy Policy; U.S. Energy Infrastructure; Latin America Power Generation; Critical Infrastructure, Infrastructure and Power Grid; CISA Guidelines in relation to COVID-19; Bulk Power Systems Executive Order
Client expense: $50,000 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
2020 · third_quarter · Energy/Nuclear
Issues related to - S. 2675 Energy Innovation Act - Energy Storage & Hydrogen; Energy Policy; U.S. Energy Infrastructure; Latin America Power Generation; Critical Infrastructure, Infrastructure and Power Grid; CISA Guidelines in relation to COVID-19; Bulk Power Systems Executive Order
Client expense: $60,000 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
2020 · third_quarter · Health Issues
Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; H.R.826, End Neglected Tropical Diseases Act; S.2675, Study, Treat, Observe, and Prevent Neglected Diseases of Poverty Act; Implementation of H.R.6201, Families First Coronavirus Response Act (P.L.116-127); Implementation of H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; Implementation of H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139); H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Energy/Nuclear
Issues related to - S. 2675 Energy Innovation Act - Energy Storage & Hydrogen; Energy Policy; U.S. Energy Infrastructure; Latin America Power Generation; Critical Infrastructure, Infrastructure and Power Grid; CISA Guidelines in relation to COVID-19; Bulk Power Systems Executive Order
Client expense: $60,000 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
2020 · second_quarter · Energy/Nuclear
Issues related to - S. 2675 Energy Innovation Act - Energy Storage & Hydrogen; Energy Policy; U.S. Energy Infrastructure; Latin America Power Generation; Critical Infrastructure, Infrastructure and Power Grid; CISA Guidelines in relation to COVID-19; Bulk Power Systems Executive Order
Client expense: $60,000 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
2020 · second_quarter · Health Issues
Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; H.R.826, End Neglected Tropical Diseases Act; S.2675, Study, Treat, Observe, and Prevent Neglected Diseases of Poverty Act; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139).
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; H.R.826, End Neglected Tropical Diseases Act; S.2675, Study, Treat, Observe, and Prevent Neglected Diseases of Poverty Act; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA) and the orphan drug tax credit; Issues related to the use of plasma therapies in COVID-19 patients; S. 1379, H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 - provisions related to reauthorization of the Pandemic and All-Hazards Preparedness Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; S. 61, H.R. 478, The Safe and Affordable Drugs from Canada Act 0f 2019 - provisions related to importation; H.R. 465, S. 102, The Prescription Drug Price Relief Act of 2019 - provisions related to foreign reference pricing, patents and march-in rights; S. 97, H.R. 447, The Affordable and Safe Prescription Drug Importation Act - provisions related to importation; S. 205, The Right Rebate Act of 2019 -provisions related to Medicaid drug rebates and drug classification; The Patient Affordability, Value and Efficiency Act (not yet introduced); S. 378, H.R. 1093, The Stop Price Gouging Act - provisions related to prescription drug pricing; S. 657, Drug Price Transparency Act - provisions related to prescription drug pricing transparency and commercial market rebates; S. 844, Short on Competition Act - provisions related to the importation of prescription drugs; H.R. 2279, S. 2546, Safe Step Act - provisions related to step therapy policy; Discussions related to amending P.L. 97-414, Orphan Drug Act; H.R. 2375, S. 64, Preserve Access to Affordable Generics and Biosimilars Act - provisions related to patent settlements; H.R. 937, Right Rebate Act of 2019 - provisions related to Medicaid drug rebates and drug classification; H.R. 3276, S. 1785, Fair AMP Act - provisions related to AMP cap, exclusion of authorized generics from AMP; H.R. 3, Lower Drug Costs Now Act of 2019 - provisions related to the establishment of programs and requirements relating to the prices of prescription drugs; S. 2675 STOP Neglected Diseases of Poverty Act - provisions related to Dengue; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 4712, Fairness in Orphan Drug Exclusivity Act - provisions related to amending P.L. 97-414, Orphan Drug Act;
2019 · fourth_quarter · Health Issues
H.R.3, Lower Drug Costs Now Act, Entirety H.R. 1309/S.851, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety H.R.748, Health Benefits Tax Repeal, Entirety Affordability of pharmaceuticals, generally S.684, Middle Class Health Benefits Tax Repeal, Entirety Treating gun violence as a public health epidemic related issues S.1357, Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act, Entirety Nurse Overtime and Patient Safety Act, Entirety Prescription Drug Affordability and Access Act, Entirety Affordable Drug Manufacturing Act, Entirety Monitor the following: H.R.1109, the Mental Health Services for Students Act of 2019, Entirety H.R.3022, Patient Access Protection Act, Entirety S.1770, Resilience Investment, Support, and Expansion from Trauma Act or the RISE from Trauma Act, Entirety H.R. 2328, Reauthorizing and Extending Americas Community Health Act , Title IV, No Surprises Act S.1895, Lower Health Care Costs Act, Entirety Universal healthcare generally H.R. 2328, Reauthorizing and Extending Americas Community Health Act , Title IV, No Surprises Act S.1895, Lower Health Care Costs Act, Entirety S.2675, Study, Treat, Observe, and Prevent Neglected Diseases of Poverty Act, Entirety H.R.934, Health Benefits for Miners Act, Entirety S.J.Res.52, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers". H.R.1603, Ban Asbestos Now Act
Client expense: $450,000 · Firm income: Not reported
2019 · fourth_quarter · Health Issues
Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; S. 205, The Right Rebate Act of 2019 -provisions related to Medicaid drug rebates and drug classification; H.R. 2279, S. 2546, Safe Step Act - provisions related to step therapy policy; Discussions related to amending P.L. 97-414, Orphan Drug Act; H.R. 937, Right Rebate Act of 2019 - provisions related to Medicaid drug rebates and drug classification; H.R. 3276, S. 1785, Fair AMP Act - provisions related to AMP cap, exclusion of authorized generics from AMP; H.R. 3, Lower Drug Costs Now Act of 2019 - provisions related to the establishment of programs and requirements relating to the prices of prescription drugs; VA MISSION Act of 2018 (P.L. 115 - 182) - provisions related to healthcare coverage after dischange from active duty; S. 2675 STOP Neglected Diseases of Poverty Act - provisions related to Dengue;
Client expense: $420,000 · Firm income: Not reported
2019 · fourth_quarter · Health Issues
Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations. Policies impacting Medicare coverage and reimbursement for clinical laboratory services. H.R.826, End Neglected Tropical Diseases Act. S.2675, Study, Treat, Observe, and Prevent Neglected Diseases of Poverty Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $940,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)